CRISPR/Cas9-Mediated Generation of COL7A1-Deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis Bullosa
June 2023
in “
bioRxiv (Cold Spring Harbor Laboratory)
”
Studysummary This study developed new immortalized keratinocyte cell lines lacking COL7A1 using CRISPR/Cas9 technology, providing a valuable model to explore the biology and treatment options for recessive dystrophic epidermolysis bullosa. Our plain-language summary of this paper — not a Tressless recommendation.
The study successfully developed multiple immortalized COL7A1-deficient keratinocyte cell lines using CRISPR/Cas9 technology to model recessive dystrophic epidermolysis bullosa (RDEB), a genetic skin disorder. The researchers achieved a 46.1% efficiency in inducing indels, primarily deletions, in the targeted gene. Out of nine single clones, two homozygous and two heterozygous COL7A1-deficient lines were established, showing no off-target effects. These cell lines lacked type VII collagen expression and exhibited increased motility compared to wild-type cells. This model provides a valuable tool for exploring RDEB biology and potential therapies.
